Circulating Bioactive Androgens in Midlife Women
نویسندگان
چکیده
منابع مشابه
Androgens in women.
The role of androgen treatment in women remains controversial. The proposed "Female Androgen Insufficiency Syndrome" (Fertility and Sterility, April 2002) describes a number of non-specific symptoms including unexplained fatigue, decreased well being/dysphoric mood and/or blunted motivation and diminished sexual function. An estimated 40% of women experience sexual dysfunction, highlighting the...
متن کاملWomen at midlife
What do we mean by ‘midlife’? It is important that we look after ourselves throughout life to live the healthiest life we can. Yet the reality is life demands often mean we cannot prioritise our own health enough. Between work and family we often don’t have the time to think much about our health until around midlife, which is the life stage when most of us have a few key realisations: • If we ...
متن کاملFormulations and use of androgens in women.
The physiology of normal androgen production in women has been poorly understood. Defining an androgen insufficiency state in women, in the absence of adrenal suppression and/or bilateral oophorectomy, has been difficult. Nevertheless, beneficial effects of androgen on many organ systems, including bone and the brain, are well documented. This review discusses the definition of androgen insuffi...
متن کاملUse of androgens in postmenopausal women.
Serum androgen levels decline with age in women, a decline already demonstrable prior to menopause. Oestrogen administration is associated with a decrease in bioavailable testosterone. Testosterone administration can lead to increases in a number of parameters of sexuality, probably by direct neural effects. Androgens also have anabolic effects on bone, and do not adversely affect lipids, espec...
متن کاملScreening for Ovarian Cancer in Midlife Women
O varian cancer accounts for only 3% of female cancers but is the fi fth leading cause of all cancer-related deaths in American women. A total of 15,520 women died from ovarian cancer in the United States in 2008.1 Nearly two-thirds are diagnosed at an advanced stage (III and IV), with a 5-year survival of approximately 33%. In contrast, the 5-year survival of women with cancers confi ned to th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Endocrinology & Metabolism
سال: 2006
ISSN: 0021-972X,1945-7197
DOI: 10.1210/jc.2006-0284